Rhythm treats rare genetic obesity disorders.
Rhythm Pharmaceuticals, Inc. (RYTM) is expected to report earnings on Tuesday, November 3, 2026, after the close. Estimated release time 07:17 ET. Consensus EPS estimate is $-0.73.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | FY2026 Q2 | $-0.81 | $-0.73 | +9.6% | $71.25M |
| 2026-05-05 | FY2026 Q1 | $-0.86 | $-0.83 | +3.5% | $60.11M |
| 2026-02-26 | FY2025 Q4 | $-0.79 | $-0.73 | +7.6% | $57.25M |
| 2025-11-04 | FY2025 Q3 | $-0.72 | $-0.82 | -13.9% | $51.30M |
| 2025-08-05 | FY2025 Q2 | $-0.66 | $-0.75 | -13.6% | $48.50M |
| 2025-05-07 | FY2025 Q1 | $-0.69 | $-0.81 | -17.4% | $32.70M |
| 2025-02-28 | FY2024 Q4 | $-0.69 | $-0.72 | -4.3% | $41.83M |
| 2024-11-06 | FY2024 Q3 | $-0.80 | $-0.71 | +11.3% | $33.25M |
RYTM has beaten consensus EPS in 4 of its last 8 reported quarters.
RYTM reported Aug 4. The highlights: EPS of -$0.73 — a beat vs the -$0.81 estimate (+10%); revenue of $71M — a beat vs the $68M consensus (+5%). Focus now shifts to Imcivree expansion.
See RYTM on the live calendar →